Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Price, News & Analysis

Bellerophon Therapeutics logo

About Bellerophon Therapeutics Stock (NASDAQ:BLPH)

Key Stats

Today's Range
$0.0070
$0.0120
50-Day Range
$0.01
$0.06
52-Week Range
$0.0116
$0.0190
Volume
N/A
Average Volume
18,907 shs
Market Capitalization
$146.80 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Receive BLPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BLPH Stock News Headlines

Bellerophon Therapeutics Inc. (BLPH) Charts
It’s not about Greenland
The petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.tc pixel
Bellerophon Therapeutics, Inc. (BLPH)
Bellerophon Therapeutics Inc (BLPH)
Bellerophon Therapeutics Inc BLPH
See More Headlines

BLPH Stock Analysis - Frequently Asked Questions

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) posted its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.42) earnings per share for the quarter.

Shares of Bellerophon Therapeutics reverse split on Monday, February 10th 2020.The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Bellerophon Therapeutics (BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Meta Platforms (META).

Company Calendar

Last Earnings
8/14/2023
Today
8/25/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:BLPH
CIK
1600132
Fax
N/A
Employees
20
Year Founded
2009

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$5.64 million
Price / Sales
0.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.27 per share
Price / Book
0.04

Miscellaneous

Outstanding Shares
12,233,000
Free Float
11,597,000
Market Cap
$146.80 thousand
Optionable
No Data
Beta
0.74

Social Links

10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:BLPH) was last updated on 8/26/2026 by MarketBeat.com Staff.
From Our Partners